LL for glioblastoma multiforme PTSR leapt nine poi
Post# of 153854
(Total Views: 678)
Posted On: 05/06/2022 4:29:30 PM
LL for glioblastoma multiforme PTSR leapt nine points to 32% in GBM
this, according to
https://www.clinicaltrialsarena.com/analysis/...ompletion/
WHY MENTION THIS?
==================
[1] GBM is not listed in the 90 LL indications on this board
[2] CYDY mirror company NWBO will announce on 5/10 Phase 3 results of thier glioblastoma therapy possible 2.5 times improved survival of patients typically only survive 14+ months.
[3] NWBO CEO Linda F. Powers I outline many check points of why she could be a CYDY CEO candidate, of course this would mean some type of CYDY/NWBO merger which would be I think amicable paring especially with Linda at the helm for all those 12 , now 13 reasons -- amicable because with NWBO NOT a big pharma firm, would not dilute the value of our investment in CYDY because LL would still be a huge influence in NWBO growth. Of course CYDY if absorbed by big pharma - we would not see big increases in our new shares in the Big Pharma company even with wild success of LL in several indications -- see Pfizer stock did not go up with the this pandemic
CONCLUDING REMARK
====================
Kind of cool that both NWBO and CYDY cross paths with glioblastoma.
If someone smarter than me here could run with this, that would be greeeeaaaat!
Later!
this, according to
https://www.clinicaltrialsarena.com/analysis/...ompletion/
WHY MENTION THIS?
==================
[1] GBM is not listed in the 90 LL indications on this board
[2] CYDY mirror company NWBO will announce on 5/10 Phase 3 results of thier glioblastoma therapy possible 2.5 times improved survival of patients typically only survive 14+ months.
[3] NWBO CEO Linda F. Powers I outline many check points of why she could be a CYDY CEO candidate, of course this would mean some type of CYDY/NWBO merger which would be I think amicable paring especially with Linda at the helm for all those 12 , now 13 reasons -- amicable because with NWBO NOT a big pharma firm, would not dilute the value of our investment in CYDY because LL would still be a huge influence in NWBO growth. Of course CYDY if absorbed by big pharma - we would not see big increases in our new shares in the Big Pharma company even with wild success of LL in several indications -- see Pfizer stock did not go up with the this pandemic
CONCLUDING REMARK
====================
Kind of cool that both NWBO and CYDY cross paths with glioblastoma.
If someone smarter than me here could run with this, that would be greeeeaaaat!
Later!
(0)
(0)